Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...

The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Kymera will lead all research activities for the CDK2 program, while Foster City, Calif., biopharmaceutical company Gilead will have global rights to develop, manufacture and commercialize all ...

Kymera Therapeutics Inc. Follow. 1 results. June 25, 2025. Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics. Gilead Sciences has entered into an option and license deal ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.